Clinical Trial

Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

Study acronym: AVATARE
Recruiting
View on ClinicalTrials.gov →
Summary
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2026-01-09
Trial Details
NCT Number NCT07119970
Lead Sponsor University Hospital, Bordeaux
Conditions Myeloproliferative Neoplasm, Myeloproliferative Disorders
Enrollment 300 participants
Start Date 2025-12-09
Primary Completion 2028-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-13